卡维地洛联合螺内酯治疗慢性心力衰竭近期疗效观察被引量：3

导出

摘要目的观察应用卡维地洛联合螺内酯治疗慢性心力衰竭患者的近期疗效。方法慢性心力衰竭患者92例,随机分为常规治疗组(对照组)和卡维地洛联合螺内酯治疗组(治疗组)各46例,治疗组在常规治疗药物的基础上加用卡维地洛和螺内酯,疗程12周。观察治疗效果并测定治疗前后左心室射血分数(LVFF)和血浆B型利尿钠肽(BNP)水平。结果治疗12周后,治疗组总有效率高于对照组(P<0.05),治疗组LVFF、BNP与对照组比较,差异均有统计学意义(P<0.05)。结论卡维地洛联合螺内酯治疗慢性心力衰竭效果显著,可降低血浆中BNP水平,改善心功能。

作者王丽

机构地区鞍山市中心医院心内科

出处《临床和实验医学杂志》 2010年第5期364-365,共2页 Journal of Clinical and Experimental Medicine

关键词卡维地洛螺内酯慢性心力衰竭 B型利尿钠肽

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献6

1王文丰,杨庭树.卡维地洛在心力衰竭治疗中的应用[J].中国临床药理学杂志,2004,20(4):309-311. 被引量：9
2Suzuki T,Yamazaki T,Yazaki Y,et al.The role of the natriuretic peptide in the cardiovascular system. Cardiovascular Research . 2001
3Shapiro BP,Chen HH,Burnett JC Jr,et al.Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure. Mayo Clinic Proceedings . 2003
4Vanderheyden,M,Goethals,M,Verstreken,S.Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. Journal of the American College of Cardiology . 2004
5The task force for the diagnosis and treatment of CHF of the European Society of Cardiology.Guidelines for the diagnosis and treatment of chronic heart failure: full text(update 2005). European Heart Journal . 2005
6Milliez,P,Girerd,X,Plouin,PF.Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology . 2005

二级参考文献16

1Bristow MR.Mechanism of action of beta-blocking agents in heart failure [J].Am J Cardiol,1997; 80:26-31.
2Richhom E J,Bristow MR.Medical therapy can improve the biological properties the chronically failing heart:a new era in the treatment of heart failure[J].Circulation,1996; 94:2258-2296.
3Hall SA,Cigarroa CG,Marooux L,et al.The course of improvement in left ventricular function,mass,and geometry in patients with congestive heart failure treated with-adrenergic blockade[J].J Am Coll Cardiol,1995; 25:1154-1161.
4MatsudaY,Akita H,Terashima M,et al.Carvedilol improves endomelium-dependent dilatation in patients with coronary artery disease [J].Am Heart J,2000; 140:753-759.
5Noguchi N,Nishino K,Niki E.Antioxidant action of the antihypertensive drug,carvedilol,against lipid peroxidation[J].Biochem Pharmacol,2000; 59:1069-1076.
6Sanderson J,Chan SKW,Yip G,et al,Beta-blocker in heart failure:A comparison of carvedilol with metoprolol[J].JAm Coll Carclid,1999; 34:1522-1528.
7Metra M,Giubbini R,Nodari S,et al.Differential effect of β-blockers in patients with heart failure.A prospective,randomized,double-blind comparison of the long-term effect of metoprolol versus carvedilol[J].Circulation,2000; 102:546-551.
8Ohtsuka T,Hamada M,Hideyuki S,et al,Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy[J].Am J Cardiol,2002;89:996-998.
9Wallhaus TR,Taylor M,DeGradeo TR,et al.Myocardial free fatty acid and glucouse use agter carvedilol treatment in patients with congestive heart failure [J].Circulation,2001; 103:1441-1446.
10Australia-New Zealand Heart Fairlure Research Collaborative Group.Randomized,placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease[J].Lancet,1997; 349:375-380.